alteminostat (CKD-581) / Chong Kun Dang - LARVOL DELTA

Comprehensive Analysis of the Prognostic Implications and Biological Function of HDACs in Liver Hepatocellular Carcinoma. (PubMed, Int J Med Sci) - "CKD-581 prohibits LIHC progression via inhibiting the cell cycle signaling pathway. CKD-581 holds promise as a therapeutic agent for the clinical management of LIHC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • CDKN1A

CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy. (PubMed, Biomol Ther (Seoul)) - "Overall, CKD-581 shows anticancer activity via inhibition of the Wnt/β-catenin signaling pathway in hematologic malignancies. This finding is evidence of the therapeutic potential and rationale of CKD-581 for treatment of MM."

IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • T Cell Non-Hodgkin Lymphoma • BCL2 • CASP3 • CCND1 • CDK4 • CDKN1A • MYC

Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma. (PubMed, Int J Mol Sci) - "In a DLBCL SCID mouse xenograft model, CKD-581 exhibited anti-cancer effects comparable with those of rituximab (CD20 mAb). Our findings suggest that CKD-581 could be a good candidate for the treatment of DLBCL."

IO Biomarker • Journal • Chronic Kidney Disease • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MCL1

CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical; Trial completion date: Nov 2019 ➔ Sep 2021; Trial primary completion date: Jun 2018 ➔ Jun 2020

Clinical • Combination therapy • Trial completion date • Trial primary completion date

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical; Trial completion date: Jun 2021 ➔ Nov 2022; Trial primary completion date: Jun 2019 ➔ Apr 2021

Clinical • Combination therapy • Trial completion date • Trial primary completion date

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM) (ASH 2019) - "Conclusions Alteminostat, a novel hydroxamate-based pan-HDAC inhibitor, can be combined safely with lenalidomide and dexamethasone, demonstrating significant clinical activity in subjects with MM. Enrollment is ongoing and full phase 1 will be updated and presented."

Clinical • Combination therapy • P1 data

CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. (PubMed, Invest New Drugs) - "Conclusion CKD-581 was well tolerated by the patients with lymphoma or MM refractory to standard therapy. It exhibited dose-proportional pharmacokinetics and modest anti-tumor efficacy."

Clinical • Journal • P1 data